A new peer-reviewed study from Dalhousie University has found that pharmacists' scope of practice can be used to provide ...

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...

The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...

A research team at the University of Iowa has identified the role of key genes and ultraviolet light in a common eye disease.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

With the CTSA funding, UB will build on its strong success improving health outcomes and addressing health disparities in WNY ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

CMS is expected to publish up to 15 drugs for the second cycle of the program by Feb. 1, and these are some of the drugs most ...

This nonfiction comic explores an intervention aimed at reducing hypertension among the congregants of several churches in ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...